De Deyn, Peter Paul, Eriksson, Hans, Svensson, Hanna

Objective: The objective of this study was to assess the safety and tolerability of extended-release quetiapine fumarate (quetiapine XR) compared with quetiapine immediate-release (quetiapine IR) in older patients with Alzheimer’s disease with symptoms of psychosis and/or agitation.; Methods: This was a 6-week, double-blind, double-dummy, randomised study. Of the 109 patients screened, 100 were randomised to […]

Vigen, Cheryl L. P., Mack, Wendy J., Keefe, Richard S. E., Sano, Mary, Sultzer, David L., Stroup, T. Scott, Dagerman, Karen S., Hsiao, John K., Lebowitz, Barry D., Lyketsos, Constantine G., Tariot, Pierre N., Zheng, Ling, Schneider, Lon S.

Objective: The impact of the atypical antipsychotics olanzapine, quetiapine, and risperidone on cognition in patients with Alzheimer’s disease is unclear. The authors assessed the effects of time and treatment on neuropsychological functioning during the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease study (CATIE-AD).; Method: CATIE-AD included 421 outpatients with Alzheimer’s disease and psychosis or agitated/aggressive […]

Zheng, Ling, Mack, Wendy J., Dagerman, Karen S., Hsiao, John K., Lebowitz, Barry D., Lyketsos, Constantine G., Stroup, T. Scott, Sultzer, David L., Tariot, Pierre N., Vigen, Cheryl, Schneider, Lon S.

Objective: The second-generation antipsychotics are associated with metabolic abnormalities in patients with schizophrenia. Elderly patients with Alzheimer’s disease are frequently treated with these antipsychotics, but limited data are available on their metabolic effects.; Method: The authors assessed 186 male and 235 female Alzheimer’s disease outpatients from the Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer’s Disease (CATIE-AD) […]

Marras, Connie, Herrmann, Nathan, Anderson, Geoffrey M., Fischer, Hadas D., Wang, Xuesong, Rochon, Paula A.

Background: Differences between atypical antipsychotics in their potential to cause parkinsonism and risk factors for antipsychotic-induced parkinsonism are not well established. There is a particular paucity of information on this in real-world use of these drugs, outside of clinical trial settings.; Objective: We compared the incidence of parkinsonism after new treatment with risperidone, olanzapine, or […]

Martínez Martínez, L., Olivera Fernández, M. R., Piñeiro Corrales, G.

Introduction: The atypical antipsychotics (AA) quetiapine, olanzapine and ziprasidone are used to treat behavioural disorders associated with dementia. This indication does not appear on their technical sheet. The object of this study is to analyse the relationship of these treatments with mortality and other factors.; Method: Retrospective study from March 2005 to July 2007 of […]